A sweeping new analysis pooling data from nearly 68,000 patients has delivered one of the clearest pictures yet of what the cholesterol-lowering drug evolocumab can do for people already living with cardiovascular disease. The systematic review and meta-analysis, published in Health Science Reports, synthesised nine randomised controlled trials and found that the drug slashed LDL cholesterol by roughly 58 milligrams per decilitre while significantly reducing heart attacks, strokes, and the need for coronary revascularisation procedures. For the millions of patients worldwide who continue to suffer heart attacks and strokes despite taking statins, the findings offer a compelling case that this injectable antibody deserves a central place in secondary prevention.
Evolocumab belongs to a class of drugs known as PCSK9 inhibitors, and its mechanism is elegantly simple at the molecular level. PCSK9 is a protein produced by the liver that binds to LDL receptors on hepatocytes and tags them for destruction. Because these receptors are the primary route by which the liver clears LDL particles from the bloodstream, destroying them means cholesterol lingers in circulation, embedding itself in arterial walls. Evolocumab is a fully human monoclonal antibody that neutralises PCSK9, preventing this degradation. The result is a dramatic increase in the recycling and surface density of LDL receptors, which accelerates the clearance of LDL particles and can lower LDL cholesterol by up to 60 percent, far beyond what statins alone typically achieve.
The new analysis was conducted under PRISMA guidelines and prospectively registered, with researchers searching five major databases through April 2025. They included only randomised controlled trials of evolocumab in adults with established cardiovascular disease, defined as prior myocardial infarction, stroke, symptomatic peripheral artery disease, or coronary revascularisation. By focusing exclusively on a single PCSK9 inhibitor rather than pooling multiple agents, the investigators aimed to produce drug-specific estimates while minimising the heterogeneity that plagues broader class-level reviews. The final dataset encompassed 67,662 patients, with 34,618 receiving evolocumab and 33,044 receiving placebo or standard therapy, spanning landmark trials such as FOURIER, its open-label extension, and EVOPACS, which enrolled patients in the immediate aftermath of acute coronary syndromes.
The lipid results were striking across the board. Beyond the headline LDL reduction of 57.73 milligrams per decilitre, evolocumab lowered total cholesterol by about 52 milligrams per decilitre and triglycerides by roughly 21 milligrams per decilitre, while modestly raising HDL cholesterol by about 3.7 milligrams per decilitre. The drug also reduced lipoprotein(a), a genetically determined, pro-atherogenic particle that statins barely touch, though the pooled reduction of about 11 milligrams per decilitre narrowly missed conventional statistical significance. The authors caution that the clinical benefit should be attributed primarily to LDL lowering, which has a firmly established causal relationship with atherosclerotic risk, while the changes in HDL and triglycerides are best viewed as accompanying metabolic effects rather than independent drivers of outcome improvement.
On the clinical side, the pooled analysis found a significant reduction in major adverse cardiovascular events, with a risk ratio of 0.53. That figure, however, demands careful interpretation. The pooled estimate is considerably larger than the roughly 15 percent relative risk reduction reported in the FOURIER trial, and the researchers attribute this discrepancy to methodological differences, including the pooling of risk ratios from aggregated event counts rather than hazard ratios from time-to-event analyses, the inclusion of smaller trials with fewer events, and variation in how composite endpoints were defined across studies. When the most influential smaller trials were excluded in sensitivity analyses, heterogeneity vanished and the effect settled at a more conservative risk ratio of 0.84, which aligns closely with the landmark trial evidence.
Individual endpoints told a consistent story. Myocardial infarction risk fell by 26 percent and coronary revascularisation by 20 percent, both with high-certainty evidence and minimal heterogeneity. Stroke showed a smaller, borderline significant reduction of 14 percent. Cardiovascular mortality and hospitalisation for unstable angina did not decline significantly, which the authors attribute to the relative rarity of these individual endpoints, the limited follow-up duration of most trials, and the fact that cardiovascular death reflects many competing mechanisms beyond LDL exposure alone. Importantly, the absence of significance for these endpoints does not negate biological benefit, given the robust reductions observed in the events that most directly reflect plaque rupture and arterial obstruction.
Safety findings were equally reassuring. Across more than 56,000 patients analysed for serious adverse events, there was no difference between evolocumab and control groups, with zero heterogeneity indicating remarkably consistent results. Rates of drug discontinuation, neurocognitive complaints, muscle-related symptoms, and new-onset diabetes were all statistically indistinguishable from placebo. The only signal was a modest, non-significant increase in mild injection-site reactions. This profile contrasts favourably with statins, which do not inhibit intracellular cholesterol synthesis and therefore avoid the muscle toxicity pathway that troubles some patients. Long-term extension data from FOURIER-OLE, following patients for nearly eight years, have similarly found no accumulation of neurological, metabolic, or hemorrhagic harms.
The authors also explored how treatment effects varied across clinical contexts. LDL reductions remained significant in every subgroup examined, ranging from about 55 to 60 milligrams per decilitre whether patients had recent acute coronary syndromes or stable disease. Lipoprotein(a) reductions were significant in acute coronary syndrome populations and in event-driven trials, while the MACE benefit was concentrated in stable atherosclerotic disease populations, imaging trials, and studies with at least one year of follow-up. These patterns reinforce the idea that the magnitude of absolute benefit scales with baseline cardiovascular risk, meaning patients with recent events, polyvascular disease, diabetes, or persistently elevated cholesterol stand to gain the most from adding evolocumab to their regimen.
The clinical implications extend to health economics as well. Current guidelines from the American College of Cardiology, the American Heart Association, and the European Society of Cardiology already recommend PCSK9 inhibitors for patients whose LDL remains at or above 70 milligrams per decilitre despite maximally tolerated statin therapy. This analysis supports that guidance, but the authors note that cost remains a barrier, with earlier cost-effectiveness analyses favourable only for the highest-risk subgroups. Insurers frequently require documented very high LDL or multiple cardiovascular events before approving coverage, a practice that effectively targets the patients most likely to benefit. As prices fall and value-based pricing models mature, access is expected to broaden.
Looking forward, the researchers call for individual participant data meta-analyses to identify which patient characteristics predict the greatest benefit, dedicated trials in patients with elevated lipoprotein(a), head-to-head comparisons with alirocumab and newer agents such as inclisiran, and real-world registries to confirm the durability of benefit beyond the trial setting. For now, the evidence solidifies a central principle of modern cardiology: when it comes to LDL cholesterol, lower is better, and evolocumab offers a powerful, safe tool for pushing levels far below what statins alone can achieve in the patients who need it most.
Subject of Research: Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with established atherosclerotic cardiovascular disease
Article Title: Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis
Article References: Goel, A., Naveed, M. A., Tandel, H., Mahmood, A., Mukhlis, M., Reddy, K. S. V., Maloth, A. K., Chauhan, A., Ashwara, A., Verma, A., & Tahir, H. B. (2026). Impact of Evolocumab on LDL‐Cholesterol and Cardiovascular Outcomes in Patients With Established CVD: Systematic Review and Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(6), Article e70355. https://doi.org/10.1002/edm2.70355
Image Credits: AI Generated
DOI: 10.1002/edm2.70355
Keywords: evolocumab, PCSK9 inhibitor, LDL cholesterol, cardiovascular disease, meta-analysis, FOURIER trial, myocardial infarction, coronary revascularisation, lipoprotein(a), statins, secondary prevention, monoclonal antibody
News Source: Ophelia Keating. (October 10, 2026). Cholesterol-Lowering Antibody Evolocumab Cuts Heart Attack Risk in Landmark Analysis. Scienmag.
